[go: up one dir, main page]

WO1997006798A3 - Pharmaceutical formulations - Google Patents

Pharmaceutical formulations Download PDF

Info

Publication number
WO1997006798A3
WO1997006798A3 PCT/EP1996/003565 EP9603565W WO9706798A3 WO 1997006798 A3 WO1997006798 A3 WO 1997006798A3 EP 9603565 W EP9603565 W EP 9603565W WO 9706798 A3 WO9706798 A3 WO 9706798A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical formulations
intolerance
clavulanate
gastro
mediator
Prior art date
Application number
PCT/EP1996/003565
Other languages
French (fr)
Other versions
WO1997006798A2 (en
Inventor
Patrick John Crowley
Original Assignee
Smithkline Beecham Plc
Patrick John Crowley
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9516584.1A external-priority patent/GB9516584D0/en
Priority claimed from GBGB9604447.4A external-priority patent/GB9604447D0/en
Application filed by Smithkline Beecham Plc, Patrick John Crowley filed Critical Smithkline Beecham Plc
Priority to JP9508930A priority Critical patent/JPH11510811A/en
Priority to EP96928455A priority patent/EP0843552A2/en
Publication of WO1997006798A2 publication Critical patent/WO1997006798A2/en
Publication of WO1997006798A3 publication Critical patent/WO1997006798A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Pharmaceutical formulations comprising clavulanate and an intolerance mediator which is a pharmaceutically acceptable salt-like derivative of a Group II metal ion and an inorganic acid are useful in treating bacterial infections, with reduced incidence of gastro-intestinal intolerance.
PCT/EP1996/003565 1995-08-12 1996-08-12 Pharmaceutical formulations WO1997006798A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP9508930A JPH11510811A (en) 1995-08-12 1996-08-12 Pharmaceutical prescription
EP96928455A EP0843552A2 (en) 1995-08-12 1996-08-12 Pharmaceutical formulations

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9516584.1A GB9516584D0 (en) 1995-08-12 1995-08-12 Pharmaceutical formulations
GB9516584.1 1996-03-01
GBGB9604447.4A GB9604447D0 (en) 1996-03-01 1996-03-01 Pharmaceuticals
GB9604447.4 1996-03-01

Publications (2)

Publication Number Publication Date
WO1997006798A2 WO1997006798A2 (en) 1997-02-27
WO1997006798A3 true WO1997006798A3 (en) 1997-04-10

Family

ID=26307569

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1996/003565 WO1997006798A2 (en) 1995-08-12 1996-08-12 Pharmaceutical formulations

Country Status (3)

Country Link
EP (1) EP0843552A2 (en)
JP (1) JPH11510811A (en)
WO (1) WO1997006798A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9815532D0 (en) * 1998-07-17 1998-09-16 Lek Pharmaceutical & Cvhemical Pharmaceutical suspension formulation
US7091212B2 (en) 2001-08-10 2006-08-15 Purdue Research Foundation Chiral dinapsoline
AU2003246791A1 (en) * 2002-04-09 2003-10-20 Flamel Technologies Oral suspension of amoxicillin capsules

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863915A (en) * 1986-04-12 1989-09-05 Beecham Group P.L.C. β-lactam antibiotics
WO1992019227A2 (en) * 1991-05-08 1992-11-12 Laboratorios Beecham Sa Pharmaceutical formulations
WO1995010290A1 (en) * 1993-10-13 1995-04-20 Warner-Lambert Company Antacid pharmaceutical composition

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863915A (en) * 1986-04-12 1989-09-05 Beecham Group P.L.C. β-lactam antibiotics
WO1992019227A2 (en) * 1991-05-08 1992-11-12 Laboratorios Beecham Sa Pharmaceutical formulations
WO1995010290A1 (en) * 1993-10-13 1995-04-20 Warner-Lambert Company Antacid pharmaceutical composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HILLEMAND: "Les antidiarrhéiques", GAZ. MED. FR., vol. 83, no. 12, 1976, pages 1213 - 1222, XP000645081 *

Also Published As

Publication number Publication date
EP0843552A2 (en) 1998-05-27
WO1997006798A2 (en) 1997-02-27
JPH11510811A (en) 1999-09-21

Similar Documents

Publication Publication Date Title
WO2001007432A3 (en) Aminopiperidine derivatives as antibacterials
AU6825300A (en) Compounds
AU694635B2 (en) Arylsulfonyl hydroxamic acid derivatives
EP0978276A3 (en) Polymer coated tablet comprising amoxycillin and clavunalate
AU2002218192A1 (en) Quinoline derivatives as antibacterials
EP1283034A3 (en) Agglomerates of beta-lactam antibiotics
CA2366304A1 (en) Novel method of treatment
AU5001496A (en) Introduction of dna into bacillus strains by conjugation
AU7445594A (en) Orally administrable opiod formulations having extended duration of effect
AU6958194A (en) Trna binding-dependent inhibition of microbial pathogen growth
AU6583696A (en) Methods for reducing inhibition of nucleic acid amplification
CA2367658A1 (en) Method for treatment of reactive arthritis or bursitis
AU1724195A (en) Novel process for the isolation of clavulanic acid and of pharmaceutically acceptable salts thereof from the fermentation broth of streptomyces sp. p 6621 ferm p 2804
AU5814096A (en) Composition comprising amoxycillin and clavulanic acid
AU1377995A (en) A method of preventing or reducing the risk of infection by bacterial pathogens utilizing simple and conjugated dextrans
AU6946491A (en) Orally active renin inhibitors
WO1997006798A3 (en) Pharmaceutical formulations
AU3471995A (en) Pharmaceutical formulations comprising clavulanic acid or derivatives and an organic acid or salt
AU4985596A (en) Novel aroylaniline derivatives, compositions and uses thereof in the treatment of viral infections
HK1045102A1 (en) Pharmaceutical formulations
HK1006571A1 (en) Clavulanic acid salts
AU2796799A (en) Amplification of gene transfer and gene therapy by controlled replication
AU1293195A (en) Composition and method for sewage treatment using fungal and bacterial enzymes
AU6391994A (en) Compounds active against aids and related infections
AU5965196A (en) Rolling incontinence plug

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref country code: JP

Ref document number: 1997 508930

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1996928455

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996928455

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996928455

Country of ref document: EP